WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2025. Recent Corporate Highlights and Upcoming Anticipated Milestones: Second Quarter 2025 Financial Update: Consolidated Balance Sheets "The team has made tremendous progress on the execution of the Phase 2 L ...